Breast Cancer
Conditions
Keywords
stage I breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer
Brief summary
RATIONALE: Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving Abraxane together with lapatinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving Abraxane together with lapatinib works in treating patients with stage I, stage II, or stage III breast cancer.
Detailed description
OBJECTIVES: Primary * Determine the clinical response rate, as measured by clinical exam and imaging studies, in patients with stage I-III breast cancer treated with neoadjuvant Abraxane in combination with lapatinib. Secondary * Determine the pathologic complete response rate in patients treated with this regimen. * Correlate proliferation (Ki67), apoptosis (cleaved caspase-3), and angiogenesis (vW, CD34) markers, measured before and after treatment, with tumor response in these patients. * Conduct other correlative studies, including epidermal growth factor receptor (EGFR), HER2/neu, matrix metalloproteinases (MMPs), and transforming growth factor (TGF-β), before and after treatment with this regimen to assess tumor response in these patients. * Determine the toxicity of this regimen in these patients. OUTLINE: This is a pilot study. Patients are assigned to 1 of 2 treatment groups. * Group 1: The first 10 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. * Group 2: The next 20 patients receive Abraxane and lapatinib (at a higher dose) as in group 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients undergo blood collection and tumor biopsies periodically for correlative biomarker studies. PROJECTED ACCRUAL: A total of 30 patients will be accrued to this study.
Interventions
DRUGlapatinib ditosylate
Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
DRUGpaclitaxel albumin-stabilized nanoparticle formulation
30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Sponsors
GlaxoSmithKline
Celgene Corporation
Northwestern University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed breast cancer * Clinical stage I-III disease * Measurable disease defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm with spiral CT scan * HER2/neu 3+ by immunohistochemistry or positive by fluorescent in situ hybridization * No known brain metastases * Hormone receptor status unspecified PATIENT CHARACTERISTICS: * Menopausal status not specified * Male or female * Life expectancy \> 12 weeks * ECOG performance status (PS) 0-1 OR Karnofsky PS 80-100% * WBC ≥ 3,000/mm\^3 * Absolute neutrophil count ≥ 1,500 mm\^3 * Platelet count ≥ 100,000/mm\^3 * Total bilirubin normal * AST and ALT ≤ 2.5 times upper limit of normal * Creatinine normal OR creatinine clearance ≥ 60 mL/min * LVEF ≥ 50% as measured by echocardiogram or MUGA scan * No other malignancy within the past year * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Able to swallow and retain oral medication * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib * No ongoing or active infection * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia * No psychiatric illness or social situation that would preclude study compliance * No other uncontrolled illness * No gastrointestinal (GI) tract disease that would preclude ability to take oral medication * No malabsorption syndrome * No requirement for IV alimentation * No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis) PRIOR CONCURRENT THERAPY: * No prior chemotherapy, immunotherapy, radiotherapy, or hormonal therapy for breast cancer * No prior treatment with epidermal growth factor receptor targeting therapies * No prior surgical procedures affecting absorption * No prior surgery for breast cancer * At least 14 days since prior and no concurrent CYP3A4 inducers, including any of the following: * Dexamethasone or dexamethasone equivalent dose ≥ 1.5 mg/day, including any of the following: * Cortisone (≥ 50 mg/day) * Hydrocortisone (≥ 40 mg/day) * Prednisone (≥ 10 mg/day) * Methylprednisolone (≥ 8 mg/day) * Phenytoin * Carbamazepine * Phenobarbital * Efavirenz * Nevirapine * Rifampin * Rifabutin * Rifapentine * Hypericum perforatum (St. John's wort) * Modafinil * At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following: * Clarithromycin * Erythromycin * Troleandomycin * Delavirdine * Ritonavir * Indinavir * Saquinavir * Nelfinavir * Amprenavir * Lopinavir * Itraconazole * Ketoconazole * Voriconazole * Fluconazole (doses up to 150 mg/day are permitted) * Nefazodone * Fluvoxamine * Verapamil * Diltiazem * Cimetidine * Aprepitant * Grapefruit or its juice * At least 6 months since prior and no concurrent amiodarone * At least 2 days since prior and no concurrent gastric pH modifiers\*, including any of the following: * Cimetidine * Ranitidine * Nizatidine * Famotidine * Omeprazole * Esomeprazole * Rabeprazole * Pantoprazole * Lansoprazole * NOTE: \*Antacids are allowed within 1 hour before and after administration of study drug * No other concurrent investigational agents * No other concurrent anticancer therapy, including chemotherapy, radiotherapy, immunotherapy, or antitumor hormonal therapy * No concurrent herbal (alternative) medicines * No concurrent combination antiretroviral therapy for HIV-positive patients * Concurrent bisphosphonates allowed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Response Rate (cRR) | At Baseline, then before each treatment cycle begins and after 4 cycles of study treatment (1 cycle = 21 days) | cRR measured by RECIST for target lesions assessed by clinical exam+ mammogram+ ultrasound (US). cRR is defined as number of patients who's best response in any of the assessments (clinical exam/mammogram/US) is CR+PR. Response will be defined as one of the following in either clinical exam, mammogram or US: Complete Response (CR)-Disappearance of all target lesions. Partial Response (PR)\>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum. Stable Disease-neither sufficient shrinkage to qualify for Partial disease nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD while on study. Progressive Disease \<=20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic Complete Response (pCR) | At baseline, then after 4 cycles of study treatment (1 cycle = 21 days ) and at surgery | Pathologic Complete Response (pCR) will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days) and at surgery. This will be defined as the number of patients that show a pCR after surgery. pCR is defined as the absence of histologic evidence of invasive tumor cells in the surgical breast specimen and axillary lymph nodes. |
| Proliferation (Ki67) Measured at Baseline and After Completion of Study Treatment | At baseline, then after 4 cycles of study treatment (1 cycle = 21 days ) | Correlation of proliferation (Ki67) will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days). Ki67 scoring was performed based on degree of staining (0= no staining, 1=weak nuclear staining, 2=moderate nuclear staining, 3=strong nuclear staining). Ki67 scores were counted on a maximum of 10 randomly selected x40 high-power fields with an eyepiece grid of 10x10 squares containing representative sections of tumor and calculated as percentage of positively stained cells to total tumor cells (Percent Score method) Ki67 labeling Index (LI) as assessed by counting a maximum of 1,000 malignant cells at x400 magnification. |
| Apoptosis (Cleaved Caspase-3) Measured at Baseline and After Completion of Study Treatment | At baseline, then after 4 cycles of study treatment (1 cycle = 21 days ) | Apoptosis/cleaved caspase-3 (CC3) will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days). Scoring was based on the degree of staining (0=more than 90% of tumor cells with no staining, 1= more than 90% of tumor cells have weak staining, 2= more than 90% of tumor cells have moderate staining, 3= more than 90% of tumor cells have strong staining). CC3 scores were counted on a maximum of 10 randomly selected x40 high-power fields with an eyepiece grid of 10x10 squares containing representative sections of tumor and calculated as percentage of positively stained cells to total tumor cells (Percent Score method) CC3 labeling Index (LI) as assessed by counting a maximum of 1,000 malignant cells at x400 magnification. |
| Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | At baseline, then after 4 cycles of study treatment (1 cycle = 21 days ) | Epidermal growth factor receptor (EGFR), HER2/neu, matrix metalloproteinases (MMPs), and transforming growth factor (TGF-β) will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days) with expressions analyzed by light microscopy in invasive breast cancer regions. MMP2 cytoplasmic staining intensity was assigned a score: 0=no reactivity, 1. =1-10% of tumor cells reactive, 2. =11-25% of tumor cells reactive, 3. = 26-50% of cells reactive, 4. = more than 50% of cells reactive Greater than or equal to 2+ score was considered positive for expression. EGFR membrane staining was assigned a score: 0 = no staining or faint staining in less than 10% of cells 1. = faint incomplete membrane staining in more than 10% of cells 2. = weak to moderate complete membrane staining of more than 10% of cells 3. = strong complete membrane staining in more than 10% of tumor cells |
| Side Effects From the Combination of Abraxane and Lapatinib | At baseline, then before the start of each study treatment cycle (1 cycle = 21 days) begins | Side effects from the combination of Abraxane and Lapatinib will be assessed using CTCAE 3.0. Side effects that were related to study treatment and grade 3 or higher were collected where: Grade 1= Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life-threatening Grade 5 = Death |
| Angiogenesis (vW, CD34) Markers as Measured at Baseline and After Completion of Study Treatment | At baseline, then after 4 cycles of study treatment (1 cycle = 21 days ) | Angiogenesis (vW, CD34) markers will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days). Expressions were analyzed by light microscopy in invasive breast cancer regions. Tumor cells were assigned a score: 0 = no staining 1. weak staining less than 1% of tumor cells 2. = medium staining in 1-10% of tumor cells/weak staining in less than 1% of tumor cells 3. = medium or strong staining in more than 10% of the tumor cells. Capillary density was assessed in breast sections stained for CD34 at a x200 magnification by counting the number of capillaries per field with five fields per slide and results expressed as the average number of capillaries per field. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Circulating Tumor Cell Measurement | At baseline, then before each study treatment cycle begins (1 cycle = 21 days) | Circulating tumor cell measurement will be assessed by lab tests done at baseline, then before each study treatment cycle begins (1 cycle = 21 days) |
Countries
United States
Participant flow
Recruitment details
The study was opened to accrual May 4th 2006 with the first patient being treated on November 10th 2006. 30 patients were enrolled and treated on the study with the study being closed to new enrollment on June 10th 2009 having reached its accrual goal.
Participants by arm
| Arm | Count |
|---|---|
| Treatment With Lapatinib and Abraxane 30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
lapatinib ditosylate: Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
paclitaxel albumin-stabilized nanoparticle formulation: 30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. | 30 |
| Total | 30 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Evaluated for and Completed SOC Surgery | Lost to Follow-up | 1 |
| Evaluated for and Completed SOC Surgery | Progressive Disease | 1 |
| Follow up for 5 Years | Data collection was stopped | 24 |
| Follow up for 5 Years | Death | 5 |
Baseline characteristics
| Characteristic | Treatment With Lapatinib and Abraxane |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 3 Participants |
| Age, Categorical Between 18 and 65 years | 27 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 29 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Region of Enrollment United States | 30 participants |
| Sex: Female, Male Female | 30 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 5 / 30 |
| other Total, other adverse events | 30 / 30 |
| serious Total, serious adverse events | 2 / 30 |
Outcome results
Primary
Clinical Response Rate (cRR)
cRR measured by RECIST for target lesions assessed by clinical exam+ mammogram+ ultrasound (US). cRR is defined as number of patients who's best response in any of the assessments (clinical exam/mammogram/US) is CR+PR. Response will be defined as one of the following in either clinical exam, mammogram or US: Complete Response (CR)-Disappearance of all target lesions. Partial Response (PR)\>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum. Stable Disease-neither sufficient shrinkage to qualify for Partial disease nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD while on study. Progressive Disease \<=20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: At Baseline, then before each treatment cycle begins and after 4 cycles of study treatment (1 cycle = 21 days)
Population: One patient did not have an ultrasound after 4 cycles of treatment prior to surgery
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment With Lapatinib and Abraxane | Clinical Response Rate (cRR) | Complete Response | 6 participants |
| Treatment With Lapatinib and Abraxane | Clinical Response Rate (cRR) | Partial Response | 18 participants |
| Treatment With Lapatinib and Abraxane | Clinical Response Rate (cRR) | Stable Disease | 5 participants |
| Treatment With Lapatinib and Abraxane | Clinical Response Rate (cRR) | Progressive Disease | 0 participants |
| Treatment With Lapatinib and Abraxane | Clinical Response Rate (cRR) | Clinical Response Rate | 24 participants |
Secondary
Angiogenesis (vW, CD34) Markers as Measured at Baseline and After Completion of Study Treatment
Angiogenesis (vW, CD34) markers will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days). Expressions were analyzed by light microscopy in invasive breast cancer regions. Tumor cells were assigned a score: 0 = no staining 1. weak staining less than 1% of tumor cells 2. = medium staining in 1-10% of tumor cells/weak staining in less than 1% of tumor cells 3. = medium or strong staining in more than 10% of the tumor cells. Capillary density was assessed in breast sections stained for CD34 at a x200 magnification by counting the number of capillaries per field with five fields per slide and results expressed as the average number of capillaries per field.
Time frame: At baseline, then after 4 cycles of study treatment (1 cycle = 21 days )
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Treatment With Lapatinib and Abraxane | Angiogenesis (vW, CD34) Markers as Measured at Baseline and After Completion of Study Treatment | CD34 Pre-treatment | 59.54 average number of capillaries per field | Standard Deviation 17.56 |
| Treatment With Lapatinib and Abraxane | Angiogenesis (vW, CD34) Markers as Measured at Baseline and After Completion of Study Treatment | CD34 Post-treatment | 73.12 average number of capillaries per field | Standard Deviation 32.83 |
| Treatment With Lapatinib and Abraxane | Angiogenesis (vW, CD34) Markers as Measured at Baseline and After Completion of Study Treatment | CD34 Difference | 14.69 average number of capillaries per field | Standard Deviation 33.47 |
| Treatment With Lapatinib and Abraxane | Angiogenesis (vW, CD34) Markers as Measured at Baseline and After Completion of Study Treatment | vWF Pre-treatment | 43.11 average number of capillaries per field | Standard Deviation 22.33 |
| Treatment With Lapatinib and Abraxane | Angiogenesis (vW, CD34) Markers as Measured at Baseline and After Completion of Study Treatment | vWF Post-treatment | 49.45 average number of capillaries per field | Standard Deviation 25.33 |
| Treatment With Lapatinib and Abraxane | Angiogenesis (vW, CD34) Markers as Measured at Baseline and After Completion of Study Treatment | vWF Difference | 4.79 average number of capillaries per field | Standard Deviation 26.07 |
Secondary
Apoptosis (Cleaved Caspase-3) Measured at Baseline and After Completion of Study Treatment
Apoptosis/cleaved caspase-3 (CC3) will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days). Scoring was based on the degree of staining (0=more than 90% of tumor cells with no staining, 1= more than 90% of tumor cells have weak staining, 2= more than 90% of tumor cells have moderate staining, 3= more than 90% of tumor cells have strong staining). CC3 scores were counted on a maximum of 10 randomly selected x40 high-power fields with an eyepiece grid of 10x10 squares containing representative sections of tumor and calculated as percentage of positively stained cells to total tumor cells (Percent Score method) CC3 labeling Index (LI) as assessed by counting a maximum of 1,000 malignant cells at x400 magnification.
Time frame: At baseline, then after 4 cycles of study treatment (1 cycle = 21 days )
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Treatment With Lapatinib and Abraxane | Apoptosis (Cleaved Caspase-3) Measured at Baseline and After Completion of Study Treatment | CC3 Pre-treatment | 84.32 Labeling Index | Standard Deviation 28.21 |
| Treatment With Lapatinib and Abraxane | Apoptosis (Cleaved Caspase-3) Measured at Baseline and After Completion of Study Treatment | CC3 Post-treatment | 76.58 Labeling Index | Standard Deviation 29.51 |
| Treatment With Lapatinib and Abraxane | Apoptosis (Cleaved Caspase-3) Measured at Baseline and After Completion of Study Treatment | CC3 Difference | -5.26 Labeling Index | Standard Deviation 35.81 |
Secondary
Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment
Epidermal growth factor receptor (EGFR), HER2/neu, matrix metalloproteinases (MMPs), and transforming growth factor (TGF-β) will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days) with expressions analyzed by light microscopy in invasive breast cancer regions. MMP2 cytoplasmic staining intensity was assigned a score: 0=no reactivity, 1. =1-10% of tumor cells reactive, 2. =11-25% of tumor cells reactive, 3. = 26-50% of cells reactive, 4. = more than 50% of cells reactive Greater than or equal to 2+ score was considered positive for expression. EGFR membrane staining was assigned a score: 0 = no staining or faint staining in less than 10% of cells 1. = faint incomplete membrane staining in more than 10% of cells 2. = weak to moderate complete membrane staining of more than 10% of cells 3. = strong complete membrane staining in more than 10% of tumor cells
Time frame: At baseline, then after 4 cycles of study treatment (1 cycle = 21 days )
Population: Data for HER2/neu and transforming growth factor (TGF-β) was not collected or analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | MMP-2 2+ : Post-treatment | 2 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | MMP-2 3+ : Post-treatment | 1 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | EGFR 0 : Pre-treatment | 21 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | EGFR 0 : Post-treatment | 18 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | EGFR 1+ : Pre-treatment | 5 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | EGFR 1+ : Post-treatment | 3 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | EGFR 2+ : Pre-treatment | 0 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | EGFR 2+ : Post-treatment | 0 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | EGFR 3+ : Pre-treatment | 0 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | EGFR 3+ : Post-treatment | 0 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | EGFR 4+ : Pre-treatment | 0 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | EGFR 4+ : Post-treatment | 0 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | MMP-2 0 : Pre-treatment | 3 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | MMP-2 0 : Post-treatment | 2 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | MMP-2 1+ : Pre-treatment | 13 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | MMP-2 1+ : Post-treatment | 10 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | MMP-2 2+ : Pre-treatment | 3 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | MMP-2 3+ : Pre-treatment | 1 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | MMP-2 4+ : Pre-treatment | 8 participants |
| Treatment With Lapatinib and Abraxane | Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment | MMP-2 4+ : Post-treatment | 4 participants |
Secondary
Pathologic Complete Response (pCR)
Pathologic Complete Response (pCR) will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days) and at surgery. This will be defined as the number of patients that show a pCR after surgery. pCR is defined as the absence of histologic evidence of invasive tumor cells in the surgical breast specimen and axillary lymph nodes.
Time frame: At baseline, then after 4 cycles of study treatment (1 cycle = 21 days ) and at surgery
Population: One patient did not have an ultrasound after 4 cycles of treatment prior to surgery and one patient was lost to follow up before undergoing surgery
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment With Lapatinib and Abraxane | Pathologic Complete Response (pCR) | 5 Count of Participants |
Secondary
Proliferation (Ki67) Measured at Baseline and After Completion of Study Treatment
Correlation of proliferation (Ki67) will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days). Ki67 scoring was performed based on degree of staining (0= no staining, 1=weak nuclear staining, 2=moderate nuclear staining, 3=strong nuclear staining). Ki67 scores were counted on a maximum of 10 randomly selected x40 high-power fields with an eyepiece grid of 10x10 squares containing representative sections of tumor and calculated as percentage of positively stained cells to total tumor cells (Percent Score method) Ki67 labeling Index (LI) as assessed by counting a maximum of 1,000 malignant cells at x400 magnification.
Time frame: At baseline, then after 4 cycles of study treatment (1 cycle = 21 days )
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Treatment With Lapatinib and Abraxane | Proliferation (Ki67) Measured at Baseline and After Completion of Study Treatment | Ki67 pre-treatment | 31.56 Labeling Index | Standard Deviation 14.47 |
| Treatment With Lapatinib and Abraxane | Proliferation (Ki67) Measured at Baseline and After Completion of Study Treatment | Ki67 post-treatment | 30.66 Labeling Index | Standard Deviation 19.86 |
| Treatment With Lapatinib and Abraxane | Proliferation (Ki67) Measured at Baseline and After Completion of Study Treatment | Ki67 Difference | -1.84 Labeling Index | Standard Deviation 21.8 |
Secondary
Side Effects From the Combination of Abraxane and Lapatinib
Side effects from the combination of Abraxane and Lapatinib will be assessed using CTCAE 3.0. Side effects that were related to study treatment and grade 3 or higher were collected where: Grade 1= Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life-threatening Grade 5 = Death
Time frame: At baseline, then before the start of each study treatment cycle (1 cycle = 21 days) begins
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment With Lapatinib and Abraxane | Side Effects From the Combination of Abraxane and Lapatinib | Fatigue grade 3 | 2 participants |
| Treatment With Lapatinib and Abraxane | Side Effects From the Combination of Abraxane and Lapatinib | Rash | 1 participants |
| Treatment With Lapatinib and Abraxane | Side Effects From the Combination of Abraxane and Lapatinib | Diarrhea | 5 participants |
| Treatment With Lapatinib and Abraxane | Side Effects From the Combination of Abraxane and Lapatinib | Bone pain | 1 participants |
| Treatment With Lapatinib and Abraxane | Side Effects From the Combination of Abraxane and Lapatinib | Pruritus | 1 participants |
| Treatment With Lapatinib and Abraxane | Side Effects From the Combination of Abraxane and Lapatinib | Nausea | 1 participants |
Other Pre-specified
Circulating Tumor Cell Measurement
Circulating tumor cell measurement will be assessed by lab tests done at baseline, then before each study treatment cycle begins (1 cycle = 21 days)
Time frame: At baseline, then before each study treatment cycle begins (1 cycle = 21 days)